XOMA Royalty (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

XOMA Royalty Corporation (NASDAQ:XOMA) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $29.74 and traded as high as $34.71. XOMA Royalty shares last traded at $34.07, with a volume of 44,912 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on XOMA. Weiss Ratings reiterated a “sell (d-)” rating on shares of XOMA Royalty in a research report on Wednesday, October 8th. Wall Street Zen upgraded XOMA Royalty from a “hold” rating to a “buy” rating in a report on Monday, August 11th. Finally, Zacks Research downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 20th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $69.50.

XOMA Royalty Price Performance

The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88. The firm has a market capitalization of $411.84 million, a price-to-earnings ratio of -21.98 and a beta of 1.12. The stock has a 50 day moving average price of $35.91 and a two-hundred day moving average price of $29.74.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. The firm had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. As a group, analysts expect that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In related news, CFO Thomas M. Burns sold 4,330 shares of XOMA Royalty stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the transaction, the chief financial officer directly owned 30,079 shares in the company, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors and hedge funds have recently made changes to their positions in XOMA. JPMorgan Chase & Co. increased its stake in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares during the period. Tower Research Capital LLC TRC increased its position in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of XOMA Royalty by 12.2% in the 2nd quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 1,775 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,019 shares in the last quarter. Finally, Opaleye Management Inc. lifted its position in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock worth $6,428,000 after purchasing an additional 2,044 shares during the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.